— INO-8875 represents new mechanism of action to treat glaucoma by targeting the trabecular meshwork — LEXINGTON Mass., — June 25, 2009 — Inotek Pharmaceuticals…
— Phase 2 study to evaluate trabodenoson in combination with latanoprost expected to begin in 2013 — LEXINGTON, MA — September 27th, 2013 — Inotek…
LEXINGTON Mass.,– April 28, 2009 Inotek Pharmaceuticals today announced that preclinical data supporting the Company’s lead clinical-stage drug candidate in glaucoma, INO-8875, will be presented…
INO-8875 currently in Phase 1/2 clinical trial, results anticipated mid-2009 LEXINGTON Mass.,– May 6, 2009 Inotek Pharmaceuticals today presented positive preclinical results supporting the Company’s…